GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Discussion] the endpoint advice in here is 3 years out of date — 49 comments in the full submission. View in context.
2.2k
c/trialwatch·submitted 12 months ago by u/milan_villalobos

[Discussion] the endpoint advice in here is 3 years out of date

Discussionbranch of 11 comments

the endpoint advice in here is 3 years out of date. It is the sort of thing everyone half-believes and nobody writes down. 3 years. Those are measured, not estimated, and not rounded up in my favour. Argued for a week about a result and then read the limitations section, which conceded most of my opponent’s point.…

Read the full submission and all 49 comments →

This branch

11 comments, started 12 months ago
u/nightowl_injector188 points·12 months ago

Push back: an open-label extension tells you about the people who stayed. That is a different question.

replysharereportpermalink
u/hsa_math59 points·12 months ago

How long was the randomised phase before any extension?

replysharereportpermalink
u/cesar_ivaturi48 points·12 months ago·edited

That is a relative risk reduction. Quoting it without the absolute numbers overstates the case considerably.

replysharereportpermalink
u/naomi_ekstrom15 points·12 months ago

open-label extensions are not the same evidence as the randomised phase

replysharereportpermalink
u/renal_outcomes_rMOD111 points·12 months ago

Press-release posts get their own flair here. Nothing wrong with them, they are just a different kind of claim.

replysharereportpermalink
u/rohan_steiner131 points·12 months ago

discontinuation rate is a result, not a footnote

replysharereportpermalink
u/anders_vermeulen29 points·12 months ago

Absolute or relative risk reduction?

replysharereportpermalink
u/gastric_emptying_g53 points·12 months ago

Is that intention-to-treat or completers?

replysharereportpermalink
[deleted]122 points·12 months ago

[deleted]

replysharereportpermalink
u/marit_laurent84 points·12 months ago

Yes — the interval is the finding. A point estimate with a wide interval is a hypothesis in a nice font.

replysharereportpermalink
load more comments (1) →

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.